To submit a poster abstract or view the submission guidelines, please visit the Call for Poster Abstracts page.

Affordable Needle-Free Measles Immunization
Presenter: Amir Genosar, CTO, Aespironics

Affordable Needle-Free Measles Immunization for Low Resources Settings Professor Robert Sievers, AktivDry (Boulder, Colorado) Amir Genosar, Aespironics (Omer, Israel) Our team has developed a needle-free, low-cost active dry powder inhaler (DPI) with performances virtually equivalent to an FDA-approved active inhaler, yet costing less than ten cents per delivered dose. Manufacturing costs of commercially available inhalers with similar performance are at the range of several dollars to over ten dollars making them cost prohibitive for vaccination in low resources settings. AktivDry also reformulated the injectable Edmonston-Zagreb live attenuated measles virus vaccine, replacing sorbitol with myo-inositol. The dry powder vaccine is stable for at least 1 year at 2-8 ºC and shows less than 1 log loss of virus infectivity at 37 ºC for 7 days. The micro-particles rapidly dissolve and the virus replicates in the aqueous film in respiratory tracts so no water-for-injection is needed. The dry powders are individually sealed in peelable blister packs to minimize bacterial contamination sometimes encountered in liquids in multi-dose vials. A measles-specific immune response was also demonstrated. Measles vaccine dry powders in unit dose packaging have the potential to effectively vaccinate infants, children, and adults, and greatly reduce vaccine wastage, avoiding many of the problems associated with liquid vaccines delivered by injection with needles. Aktiv-Dry has joined effort with inhalers-technologies-developer Aespironics to co-develop a single-dose vaccine delivery inhaler for infants and other non-cooperating patients. Aespironics obtains a superior technology for high efficient aerosolization of dry-powder medications. Supported in part by FNIH.

Contact: amir.genosar@aespira.com

View Poster as PDF (coming soon)

---

Submit a comment:

Comments:

No comments are currently available for this entry.
You can add a comment by using the comment form above.